The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and ...

Patients with high-risk chronic myeloid leukaemia (CML) who undergo allogeneic haematopoietic stem cell transplantation (HSCT) may benefit from continuing with tyrosine kinase inhibitor (TKI) therapy, ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Patients with CML, unlike patients with acute lymphoblastic leukemia, are likely to have a longer life expectancy with and ...

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. By way of ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Hematologic outcomes of MDS treatment with hypomethylating agents in community practice. Background: Management of CML has been transformed by targeted therapies like TKI. It has been described in ...

Chronic myeloid leukaemia (CML) is a clonal haematopoietic stem cell disorder driven by the BCR–ABL fusion gene, which produces a constitutively active tyrosine kinase. This aberrant protein fosters ...

Newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia had better outcomes when receiving Scemblix, compared with a different TKI, a study found. Treatment with ...

Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite ...